Clene’s (CLNN) “Buy” Rating Reaffirmed at D. Boral Capital

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 288.51% from the company’s current price.

Several other brokerages have also recently commented on CLNN. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, UBS Group reaffirmed a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.60.

Clene Stock Performance

NASDAQ CLNN traded up $0.34 during trading on Thursday, hitting $5.92. The stock had a trading volume of 71,669 shares, compared to its average volume of 90,014. Clene has a 12 month low of $2.28 and a 12 month high of $13.50. The company’s 50-day moving average price is $4.98 and its two-hundred day moving average price is $6.70. The company has a market capitalization of $64.23 million, a PE ratio of -1.75 and a beta of 0.62.

Insider Activity

In related news, major shareholder Chidozie Ugwumba sold 15,284 shares of Clene stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $4.32, for a total value of $66,026.88. Following the transaction, the insider directly owned 565,045 shares of the company’s stock, valued at $2,440,994.40. This trade represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 301,357 shares of company stock worth $1,638,954. Company insiders own 35.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLNN. Jones Financial Companies Lllp bought a new stake in shares of Clene during the 3rd quarter valued at approximately $29,000. Jane Street Group LLC acquired a new stake in Clene in the second quarter valued at $47,000. State Street Corp raised its position in shares of Clene by 138.4% during the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after acquiring an additional 17,300 shares during the last quarter. PEAK6 LLC bought a new position in Clene during the 4th quarter worth approximately $294,000. Finally, Lunt Capital Management Inc. raised its stake in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after buying an additional 1,250 shares during the last quarter. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).